Preeclampsia: Does it involve an imbalance in regulatory immune cells?

Expert Review of Obstetrics and Gynecology

Volumn 5, Issue 2, 2010, Pages 165-168

  Hahn, Sinuhe ^a   Hasler, Paul ^b   Hoesli, Irene ^a   Lapaire, Olav ^a  

^a UNIVERSITY WOMEN S HOSPITAL   (Switzerland)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

Fetal graft rejection; Preeclampsia; Regulatory T cells; Therapy

Indexed keywords

ENDOGLIN; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN EXPRESSION; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; NOTE; PREECLAMPSIA; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; TH17 CELL;

EID: 77949386215     PISSN: 17474108     EISSN: None     Source Type: Journal    
DOI: 10.1586/eog.10.3     Document Type: Note

References (16)

1. Billington WD. The immunological problem of pregnancy: 50 years with the hope of progress. A tribute to Peter Medawar. J. Reprod. Immunol. 60, 1-11 (2003).
2. Hahn S, Gupta AK, Troeger C, Rusterholz C, Holzgreve W. Disturbances in placental immunology: ready for therapeutic interventions? Springer Semin. Immunopathol. 27, 477-493 (2006).
3. Le Bouteiller P. HLA-G in the human placenta: expression and potential functions. Biochem. Soc. Trans. 28, 208-212 (2000).
4. Hunt JS, Vassmer D, Ferguson TA, Miller L. Fas ligand is positioned in mouse uterus and placenta to prevent traffcking of activated leukocytes between the mother and the conceptus. J. Immunol. 158, 4122-4128 (1997).
5. Uckan D, Steele A, Wang BY et al. Trophoblasts express Fas ligand: a proposed mechanism for immune privilege in placenta and maternal invasion. Mol. Hum. Reprod. 3, 655-662 (1997).
6. Sedlmayr P, Blaschitz A, Wintersteiger R et al. Localization of indoleamine 2,3-dioxygenase in human female reproductive organs and the placenta. Mol. Hum. Reprod. 8, 385-391 (2002).
7. Tafuri A, Alferink J, Moller P, Hammerling GJ, Arnold B. T cell awareness of paternal alloantigens during pregnancy. Science 270, 630-633 (1995).
8. Basten A, Fazekas de St Groth B. Special regulatory T-cell review: T-cell dependent suppression revisited. Immunology 123, 33-39 (2008).
9. Terness P, Kallikourdis M, Betz AG, Rabinovich GA, Saito S, Clark DA. Tolerance signaling molecules and pregnancy: IDO, galectins, and the renaissance of regulatory T cells. Am. J. Reprod. Immunol. 58, 238-254 (2007).
10. + T cells in healthy pregnancy but not in preeclampsia. J. Immunol. 183(11), 7023-7030 (2009).
11. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 308, 1592-1594 (2005).
12. + regulatory T-cell subset. Immunology 112, 38-43 (2004).
13. Levine RJ, Lam C, Qian C et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 355, 992-1005 (2006).
14. Venkatesha S, Toporsian M, Lam C et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12, 642-649 (2006).
15. Steinborn A, Haensch GM, Mahnke K et al. Distinct subsets of regulatory T cells during pregnancy: is the imbalance of these subsets involved in the pathogenesis of preeclampsia? Clin. Immunol. 129, 139-145 (2008).
16. Gadina M, O'Shea JJ. Immune modulation: turncoat regulatory T cells. Nat. Med. 15, 1365 (2009).